BIESF Stock - Biotest AG
Unlock GoAI Insights for BIESF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $726.20M | $684.60M | $516.10M | $515.60M | $484.20M |
| Gross Profit | $223.80M | $280.30M | $124.90M | $80.70M | $130.10M |
| Gross Margin | 30.8% | 40.9% | 24.2% | 15.7% | 26.9% |
| Operating Income | $94.50M | $143.50M | $-16,600,000 | $-47,100,000 | $-1,300,000 |
| Net Income | $26.40M | $127.00M | $-31,700,000 | $-63,400,000 | $-31,400,000 |
| Net Margin | 3.6% | 18.6% | -6.1% | -12.3% | -6.5% |
| EPS | $0.71 | $3.21 | $-0.80 | $-1.61 | $-0.79 |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Visit WebsiteEarnings History & Surprises
BIESFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | $-0.60 | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.10 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.27 | — | — |
Q3 2024 | Jul 30, 2024 | — | $0.26 | — | — |
Q2 2024 | May 7, 2024 | — | $0.80 | — | — |
Q1 2024 | Mar 28, 2024 | — | $1.07 | — | — |
Q3 2023 | Sep 30, 2023 | — | $2.31 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.60 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.58 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.07 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.36 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.41 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.95 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.14 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-0.30 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.13 | — | — |
Q2 2021 | May 11, 2021 | — | $-0.44 | — | — |
Q1 2021 | Feb 11, 2021 | — | $0.01 | — | — |
Latest News
Frequently Asked Questions about BIESF
What is BIESF's current stock price?
What is the analyst price target for BIESF?
What sector is Biotest AG in?
What is BIESF's market cap?
Does BIESF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIESF for comparison